The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization

被引:3
|
作者
Sun, Bo [1 ,2 ,3 ]
Zhang, Lijie [1 ,2 ,3 ,4 ]
Xiang, Dongqiao [1 ,2 ,3 ]
Li, Qing [1 ,2 ,3 ]
Ren, Yanqiao [1 ,2 ,3 ]
Cao, Yanyan [1 ,2 ,3 ]
Sun, Tao [1 ,2 ,3 ]
Zhang, Weihua [1 ,2 ,3 ]
Wu, Linxia [1 ,2 ,3 ]
Zhu, Licheng [1 ,2 ,3 ]
Chen, Lei [1 ,2 ,3 ]
Zhao, Huangxuan [1 ,2 ,3 ]
Zheng, Chuansheng [1 ,2 ,3 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Radiol, Wuhan 430022, Peoples R China
[2] Hubei Prov Key Lab Mol Imaging, Wuhan 430022, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Intervent Radiol, Wuhan 430022, Peoples R China
[4] Peoples Liberat Army Gen Hosp, Med Ctr Chinese 5, Dept Intervent Radiol, Beijing 100039, Peoples R China
基金
中国国家自然科学基金;
关键词
RISK; COMBINATION; CIRRHOSIS; THERAPY; CANCER; HCC;
D O I
10.1155/2022/7062105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Alcohol consumption can increase the risk of developing hepatocellular carcinoma (HCC). However, whether continuous alcohol consumption can influence outcomes in patients with HCC who undergo transarterial chemoembolization (TACE) remains unclear. This study aimed to explore the effect of alcohol consumption in patients with unresectable HCC who underwent TACE. Methods. The data used in the study were obtained from two centers and were retrospectively reviewed between January, 2014, and December, 2021. 254 patients with TACE were included in this study. Among them, 101 patients were continuous alcohol consumers and 153 patients had alcohol abstinence. Propensity score matching (PSM) and competing risk analysis were used to reduce the selection bias. Results. The median overall survival (mOS) and median progression-free survival (mPFS) in the alcohol consumers' group were longer than those in the alcohol abstinence group, before and after PSM. Multivariate regression analysis showed that alcohol consumption increased all-cause mortality risk (HR: 1.486, 95% CI: 1.074-2.055; P=0.016) and tumor progression risk (HR: 1.434, 95% CI: 1.091-1.886; P=0.01) more than that with alcohol abstinence. In the competing risk analysis, after excluding deaths caused by other reasons, alcohol consumption increased cancer-specific mortality risk more than alcohol abstinence did before and after PSM. Adverse event analysis showed that alcohol consumption increased the risk of all grades of nausea and vomiting and grade III or IV nausea more than alcohol abstinence did after patients underwent TACE. Conclusion. Alcohol consumption may lead to a poor prognosis and increase adverse events in patients receiving TACE compared to those with alcohol abstinence.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Pawlik, Timothy M.
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
  • [2] Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Jie Wu
    Lei Song
    Dan-Yi Zhao
    Bing Guo
    Jing Liu
    World Journal of Gastroenterology, 2014, (31) : 10960 - 10968
  • [3] Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Wu, Jie
    Song, Lei
    Zhao, Dan-Yi
    Guo, Bing
    Liu, Jing
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (31) : 10960 - 10968
  • [4] Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review
    Manjunatha, Nisha
    Ganduri, Vinutna
    Rajasekaran, Kruthiga
    Duraiyarasan, Shrimahitha
    Adefuye, Mayowa
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [5] Transarterial chemoembolization in children to treat unresectable hepatocellular carcinoma
    Weiss, Krista E.
    Sze, Daniel Y.
    Rangaswami, Arun A.
    Esquivel, Carlos O.
    Concepcion, Waldo
    Lebowitz, Edward A.
    Kothary, Nishita
    Lungren, Matthew P.
    PEDIATRIC TRANSPLANTATION, 2018, 22 (04)
  • [6] Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma
    Jaeger, HJ
    Mehring, UM
    Castaneda, F
    Hasse, F
    Blumhardt, G
    Loehlein, D
    Mathias, KD
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 1996, 19 (06) : 388 - 396
  • [7] Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
    Long, Jianwu
    Liu, Longfei
    Yang, Xuefeng
    Lu, Xianzhou
    Qin, Lei
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2023, 39 (06) : 1847 - 1852
  • [8] Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?
    Burroughs, Andrew
    Samonakis, Dirnitrios
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2004, 1 (02): : 78 - 79
  • [9] Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma
    Wang, Peng
    Sheng, Lili
    Wang, Guoxiang
    Wang, Heping
    Huang, Xinyu
    Yan, Xiaoxing
    Yang, Xiaohua
    Pei, Renguang
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (02) : 203 - 206
  • [10] Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?
    Andrew Burroughs
    Dimitrios Samonakis
    Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1 : 78 - 79